Analyst Price Target is $7.00
▲ +2,723.72% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Notable Labs in the last 3 months. The average price target is $7.00, with a high forecast of $9.00 and a low forecast of $5.00. The average price target represents a 2,723.72% upside from the last price of $0.25.
Current Consensus is
Moderate Buy
The current consensus among 2 investment analysts is to moderate buy stock in Notable Labs. This rating has held steady since September 2024, when it changed from a Buy consensus rating.
Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California.
Read More